A synthetic hexapeptide growth hormone secretagogue distinguished by its dual activity: potent GH release via GHS-R1a plus direct cardioprotective effects through CD36 scavenger receptor binding — independent of GH. Hexarelin is the only GHRP with demonstrated cardiac receptor activity, reducing infarct size and protecting cardiomyocytes in ischemia-reperfusion models. Its longer half-life (~70 min) compared to other GHRPs allows less frequent dosing.
Research FocusCardioprotection, ischemia-reperfusion injury, cardiac CD36 biology, GH secretion
ReconstitutionBacteriostatic water — 2 mg/mL
Stability21 days at 2–8°C
Key distinction: Only GHRP with direct cardioprotective activity via CD36 — produces cardiac benefits independent of growth hormone, enabling isolated study of GHRP-cardiac receptor interactions.
Scientific Evidence
Published Research
[1]
Bisi G et al. Cardiac effects of hexarelin in hypopituitary adults. Eur J Pharmacol 1999;381:31-38 — PubMed 10528131
[2]
Locatelli V et al. Growth hormone-releasing peptides and their analogs. Endocr Rev 1999;20:382-413 — PubMed 10368775
Research Use Only. All products sold by Lumen Peppers are intended solely for in vitro research and laboratory purposes. They are not drugs, supplements, or foods. Nothing on this page constitutes medical advice. Researchers are responsible for compliance with all applicable regulations. Last updated: April 14, 2026.